Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GAA | P10253 | 1/20 | 0.36 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.36 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.36 |
| ▸ | AR | P10275 | 5/20 | 0.35 |
| ▸ | P2RX1 | P51575 | 2/20 | 0.34 |
| ▸ | POLB | P06746 | 1/20 | 0.34 |
| ▸ | P2RX4 | Q99571 | 1/20 | 0.34 |
| ▸ | P2RX7 | Q99572 | 1/20 | 0.34 |
| ▸ | GLA | P06280 | 1/20 | 0.34 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.33 |
| ▸ | RAB9A | P51151 | 1/20 | 0.33 |
| ▸ | MAPT | P10636 | 1/20 | 0.33 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.33 |
| ▸ | SLC6A9 | P48067 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3599843 | 0.89 | AR (0.40) | GAAARPOLBGLAMAPT | |
| SCHEMBL3606700 | 0.85 | KDM4E (0.36) | POLBGLASMN1; SMN2RAB9AMAPT | |
| SCHEMBL3596100 | 0.85 | RXRA (0.43) | GAAARPOLBGLAMAPT | |
| SCHEMBL3600090 | 0.84 | AR (0.37) | GAAARPOLBGLAMAPT | |
| SCHEMBL3600045 | 0.84 | AR (0.37) | GAAARPOLBGLAMAPT | |
| SCHEMBL3597829 | 0.80 | AR (0.35) | GAAARPOLBGLAMAPT | |
| SCHEMBL3600834 | 0.77 | GPBAR1 (0.33) | ARPOLB | |
| SCHEMBL3597872 | 0.75 | RXRA (0.41) | — | |
| SCHEMBL3990564 | 0.74 | GAA (0.34) | GAAMAPK1RXFP1ARP2RX1 | |
| SCHEMBL3609964 | 0.74 | KDM4E (0.42) | GAAARPOLBGLASMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100087432-A1 | PYRROLE DERIVATIVES HAVING CRTH2 RECEPTOR ANTAGONIST ACTIVITY | NOVARTIS AG (CH) | 2010-04-08 | — | — | US | disclosed |
| US-20090209552-A1 | Organic Compounds | NOVARTIS AG | 2009-08-20 | — | — | US | disclosed |
| EP-2032555-A1 | PYRROLE DERIVATIVES WITH CRTH2 RECEPTOR MODULATOR ACTIVITY | Novartis AG (CH) | 2009-03-11 | — | — | EP | disclosed |
| WO-2007144127-A1 | PYRROLE DERIVATIVES WITH CRTH2 RECEPTOR MODULATOR ACTIVITY | NOVARTIS AG (CH) | 2007-12-21 | — | — | WO | disclosed |
| EP-1828172-A1 | PYRROLE DERIVATIVES HAVING CRTH2 RECEPTOR ANTAGONIST ACTIVITY | Novartis AG (CH) | 2007-09-05 | — | — | EP | disclosed |
| WO-2006063763-A1 | PYRROLE DERIVATIVES HAVING CRTH2 RECEPTOR ANTAGONIST ACTIVITY | NOVARTIS AG (CH) | 2006-06-22 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090209552-A1 | Organic Compounds | SLCO1B3, SLCO1B1, SLC10A6 | GAA 2691/4885MAPK1 3207/4885RXFP1 562/4885 |
| US-20100087432-A1 | PYRROLE DERIVATIVES HAVING CRTH2 RECEPTOR ANTAGONIST ACTIVITY | PRLHR, AVPR2, CRHR2 | GAA 3936/4885MAPK1 1837/4885RXFP1 50/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.